Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

Benzinga

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Barchart

The innovative new treatment which could help cancer patients avoid surgery

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common cancer in women

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

International Business Times UK

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Only 3 Dividend Kings You’ll Ever Need for a Lifetime of Income

Three Dividend Kings with decades of dividend growth and strong financials are poised to deliver reliable income and stability for investors in 2025.

Barchart

Texas Sues Johnson & Johnson for 'Hiding' Tylenol Autism Risks — Billions at Stake in Landmark Case

Texas sues Tylenol's makers over autism risks, echoing Trump-era legal battles over health misinformation with potential billions at stake.

International Business Times UK

Texas sues Tylenol makers alleging deceptive marketing to pregnant people

Lawsuit comes after Trump’s baseless claims that acetaminophen can cause autism and ADHD in children

The Guardian - US

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

Benzinga

Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk

Texas Attorney General Ken Paxton is accusing the companies behind Tylenol of deceptively marketing the pain reliever to pregnant mothers

The Independent UK

Texas Attorney General Targets Tylenol Makers in Controversial Autism Lawsuit

Texas Attorney General Ken Paxton sues Johnson & Johnson and Kenvue, alleging they hid risks linking prenatal Tylenol use to autism and ADHD in children.

International Business Times UK

Texas sues Tylenol makers over RFK Jr autism claims saying they failed to state ‘risk of taking drug while pregnant’

State Attorney General Ken Paxton parroted claims by the Health Secretary which have been strongly refuted by medical professionals

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Barchart

5 Safe Income Stocks Still Worth Owning

These companies have maintained their records of paying and increasing dividends.

MarketBeat

Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

Evening Standard

Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

64-Year-Old Blames Johnson & Johnson for Her Ovarian Cancer — Joins 3,000 Suing the Pharma Giant

UK's first talc cancer group claim accuses Johnson & Johnson and Kenvue of failing to warn about asbestos risk — £1 billion suit backed by 3,000 claimants.

Benzinga

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

On Thursday, Johnson Johnson (NYSE:JNJ) announced positive topline results from a recent study.

The Guardian - UK

Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

International Business Times UK

The Real Reason Johnson & Johnson Switched to Corn Starch — Too Late to Save Its Reputation?

Johnson & Johnson's belated shift from talc to corn starch in its baby powders came amid mounting litigation—but can it repair the damage to its reputation?

Benzinga

Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims

Thousands of claimants in the U.K. are suing Johnson Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is one of the largest product liability claims of its kind to reach the High Court in…

Benzinga

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

The Independent UK

Johnson & Johnson faces UK lawsuit over cancer claims

IN FULL

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.